Early treatment of infants with spinal muscular atrophy (SMA) can drastically improve motor function for patients, explained Jill Jarecki, PhD, chief scientific officer at Cure SMA.
Early treatment of infants with spinal muscular atrophy (SMA) can drastically improve motor function for patients, said Jill Jarecki, PhD, chief scientific officer at Cure SMA.
Transcript
What do we know about the importance of treating early in infants with SMA?
Jarecki: So, SMA is a motor neuron disease. Motor neurons are dysfunctional and eventually lost. Neurons are a cell type that cannot be regenerated once lost. So, we know that it is important to intervene prior to the loss of motor neurons. And for many years, we've known that mouse models of SMA require an early window of treatment for SMN- [survivor motor neuron] enhancing drugs to have full benefit. And in patients, we've known for many years that electrophysiological experiments in SMA Type 1 infants have denervation of muscle approaching 90% by 6 months of age.
So, we believe it's very important that infants are treated presymptomatically through newborn screening. And there's been further clinical trial data and there are clinical trials looking at presymptomatic infants with all of the FDA approved drugs, but the only one that's been peer reviewed and published so far was called the NURTURE trial from Biogen looking at Spinraza [nusinersen].
There, they've shown dramatic benefits over symptomatic treatment. With presymptomatic treatment of infants under 6 months of age, you now have a Type 1 infant who would not sit, typically not be able to eat on their own, and need extensive respiratory support. Now, 100% of those babies treated presymptomatically are sitting, 100% are crawling, 100% are standing, and 88% are walking independently.
So, there really are dramatic gains with presymptomatic treatment was Spinraza. And we expect to see the same with the other SMN upregulating drugs when those results are published.
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen